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INTRODUCTION 
The drug delivery to the respiratory tract has become an 
important and effective method for treatment of pulmonary 
diseases such as chronic obstructive pulmonary diseases 
including asthma, bronchitis, emphysema, lung abscess 
etc.1 Pulmonary drug delivery methods have traditionally 
focused on one of two strategies: (i) drug suspension 
dissolution in liquid aerosol drops and (ii) mixtures of dry 
drug particulates with dry carrier particles typically 
composed of sugars.2Dry powder inhalers (DPIs) are the 
devices through which a dry powder formulation of an 
active drug is delivered for local or systemic effect via the 
pulmonary route. DPIs have number of advantages over 
metered dose inhalerssuch as direct delivery of drug into 
the deep lungs, propellant free, less bulky and have fewer 
handling errors.3The delivery of micron sized dry powder 
particulates to the respiratory tract using dry powder 
inhalers (DPI), has become commonplace in the 
prophylactic treatment of asthma and other bronchial 
related diseases. 
In case of dry powder inhaler, in order to reach the lower 
respiratory tract and optimize systemic drug absorption, 
dry powder aerosols need to present aerodynamic 
diameters between 1–5 µm.4Recently, natural chitosan 
material has attracted great attention in pharmaceutical and 
biomedical ﬁelds because of its advantageous biological 
properties, such as biodegradability, biocompatibility, and 
nontoxicity. Chitosan is a cationic polysaccharide obtained 
by partial deacetylation of chitin, the major component of 
crustacean shells.5Chitosan microspheres/microparticles 
can be prepared by number of techniques such as solvent 
evaporation, emulsification/ internal gelation, 
coacervationand spray drying.6 
Spray drying technique is widely used in the 
pharmaceutical industries because of its numerous 
advantages over other methods. The advantage of spray 
drying technique for application to microencapsulation is 
that it is reproducible, rapid and easy to scale up. Spray 
drying technique can be used to produce dry powders, 
granules or agglomerates from drug-excipient solutions 
and suspensions. The particle size of the microparticles 
prepared by spray drying technique ranged from microns 
to several tens of microns and had a relatively narrow 
distribution.7 
Salbutamol sulphate was selected as a model drug for dry 
powder formulations in treatment of respiratory 
diseases.Salbutamol sulphate, is a ß2- adrenoreceptor 
agonist and currently one of the most prescribed 
bronchodilators for the treatment of bronchial asthma.8 
Thus the aim of the present research was to prepare, 
chitosan microspheres containing salbutamol by a spray 
drying method and the effects of concentration of citric 
acid on microsphere properties 
MATERIALS & METHODS 
Materials: 
Salbutamol sulphate was obtained as a gift sample from 
Rankem, Mumbai (India), Chitosan was kind donationby 
Srividya Enterprises, Ratnagiri, India. Citric acid was 
obtained from Loba Chemicals, India. Spray 
driedlactose(Inhalac®250) was donated by Anshul India 
Pvt Ltd. Chennai, India as a gift sample. All other 
chemicals and solvents used were of analytical grade. 
Methods: 
Preparation of spray dried microspheres: 
To 100 ml of 0.5 % acetic acid solution,weighed quantity 
of chitosan (0.5 % w/v) was added with continuous stirring 
on a magnetic stirrer at 100 rpm for about 1 hr for 
complete dissolution of chitosan. When the clear solution 
was formed, Salbutamol sulphate was added. After that 5 
ml of citric acid solution as cross linking agent in the 
concentrations (0 % w/v, 0.4 % w/v, 0.8 % w/v, 1.2 % w/v, 
and 1.6 % w/v) were added to give 5 formulations. The 
formulations were spray dried byLabultima spray dryer 
(LU-222) with standard 0.7 mm nozzle. The spray drying 
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conditions such as inlet temperature, outlet temperature, 
pump rate, pressure and aspirator setting were set as 1500 -
1700 C, 1400C-150°C, 3 ml/min, 2 kg/cm2 and 65nm3/hr. 
respectively. DPI formulations of microspheres were 
prepared with carrier. The drug loaded microspheres were 
mixed with lactose carrier (Inhalac®250) in mass ratio of 
1:66.5 using a polybag for 5 min; further the mixture was 
passed through 100# and stored in a glass vial in a 
desiccator.7, 9 
Evaluation of Salbutamol-chitosan microspheres: 
Morphological characterization of microspheres: 
Surface morphology of spray dried chitosan microspheres 
was studied by using scanning electron microscope (Jeol 
JSM 6360, Japan).Spray dried powders were mounted onto 
separate, adhesive coated aluminium stubs. Excess powder 
was removed by tapping the stubs sharply and then gently 
blowing a jet of particle free compressed gas across each. 
The SEM was operated at high vacuum with accelerate 
voltage of 10 kv.10 
Particle Size Analysis: 
The particle size was determined by Motic microscope. 
The photograph of spray dried chitosan microsphere 
mounted on the slide was taken. Using the motic image 
plus software particle size of 100 particles was measured.11 
X-Ray Diffraction study:  
The physical state of the pure drug (Salbutamol sulphate) 
and in the spray dried chitosan microspheres were assessed 
by XRD studies. X ray diffraction patterns of pure drug, 
chitosan microspheres loaded with drug were obtained 
using XRD Diffractometer Philips PW 1830  instrument 
operated at 40 kV and a current of 30 mA with Cu Kα 
radiation within the range (2θ): 00 -50012 
Differential Scanning Calorimetry: 
The characteristics of the pure drug and microspheres were 
determined using differential scanning 
calorimetry(DSC60, Shimadzu). The scanning rate was 
10°C/min, and the scanning temperature range was in 
between 30°C and 300°C 13 
Entrapment Efficiency: 
For the assessment of entrapment of the drug into the 
microspheres, following method was used. Weighed 
quantity of microspheres was added to phosphate buffer 
solution (pH-7.4) and kept for 24 to extract the drug from 
the microspheres.After that the solution was filtered and 
assayed by UV-Visible spectrophotometer at 276 nm.The 
actual amount of drug loaded is relative to theoretical 
amount in microspheres was calculated in percentage and 
expressed as entrapment efficiency.14 
Encapsulation efficiency= [Encapsulated drug / total 
amount of drug] x 100. 
Flow properties of powder: 
The good flow property of drug – carrier mixture is very 
important for administration of DPI.For that, the blend of 
microspheres with spray dried lactose (Inhalac®250) was 
subjected to the flow properties of powder tests 
includingangle of repose, bulk density, tapped density, 
Carr’s index, Hausner ratio.15 
Drug content of dry powder formulation of Salbutamol 
sulphate-Chitosan microspheres: 
Accurately weighed 100 mg blend of microsphere and 
carrier were dissolved in 50 ml phosphate buffer solution 
(pH 7.4) by stirring on magnetic stirrer for 1 hr. This 
solution was further kept for 24 hrs. & stirred, filtered, 
diluted suitably & analysed by Shimadzu 1800 UV-
Spectrophotometer at 276 nm. 
In-Vitro Dissolution study: 
Dissolution test was performed on a USP Type II tablet 
dissolution test apparatus (Electrolab) at a stirring speed of 
150 rpm. A  Himedia dialysis membrane-150 with average 
flat width (42.44 mm), average diameter (25.4 mm) and 
capacity approx. (5.07 ml/cm) cut into equal pieces of 
about 5 cm x 3 cm and pre-treated with phosphate buffer 
7.4. Microspheres (50 mg) were accurately weighed out on 
the pre-treated dialysis membrane and sealed with clips. 
The pouch thus formed was attached to the paddles of the 
apparatus using cotton threads over the clips. 900 ml of 
phosphate-buffer, pH 7.4, was used as dissolution medium, 
volumes of sample was replaced with equal quantity of 
fresh dissolution medium to ensure sink condition.Samples 
were withdrawn for analysis at specified time intervals, 
and analysed for salbutamol sulphate content by UV 
spectroscopy (Shimadzu UV-1800, Japan) at λmax 276 
nm.14 
RESULT & DISCUSSION 
Morphological characterization of microspheres: 
The SEM image of the drug loaded chitosan microspheres 
is shown below. The irregular shape of microspheres may 
be due to effect of crosslinking agent. 
 
Figure 1: SEM Image of drug loaded chitosan 
microspheres (1000X) (Formulation F2) 
Particle Size Analysis:
 
The particles produced from the spray drying technique 
were in size range between 3 – 3.5 µm. (Table 1) for both 
batches indicating that there is a very little effect of 
crosslinking agent on the particle size.The particle size was 
found within the range required for dry powder inhaler. 
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Table 1: Particle size, % Entrapment & Drug content of Salbutamol – Chitosan microspheres 
Formulation 
code 
Crosslinking agent (% w/v) Particle size (µm) % Entrapment Drug content (mg) 
F1 0 3.21 81.42 1.206 
F2 0.4 3.31 79.25 1.174 
F3 0.8 3.15 78.55 1.163 
F4 1.2 3.17 78.21 1.158 
F5 1.6 3.25 77.89 1.153 
 
X-Ray Diffraction study:  
Fig.2 shows X-ray diffraction patterns of salbutamol 
sulphatepure, and spray dried drug loaded chitosan 
microspheres. The peaks on X-ray diffractogram indicate 
the crystalline form of Salbutamol sulphatepure form, but 
these peaks were not observed in chitosan microspheres. 
The spray dried microspheres showed peaks of salbutamol 
sulphate having less intensity than pure form indicating 
entrapment of drug within the polymer. 
 
 
(a) 
 
(b) 
Figure 2: X-Ray Diffractgrams of Salbutamol sulphate (a) & drug loaded Chitosan microsphreres (b) 
 
Differential Scanning Calorimetric (DSC) Analysis: 
The DSC graphs of salbutamol sulphate (a) and 
salbutamol sulphate-loaded microspheres (b) are 
presented in Figure 3. The DSC Thermograph of pure 
drug shows a sharp endothermic melting peak with the 
onset of about 210ºC reaching maximum at 216ºC. The 
DSC curve of salbutamol sulphate-loaded microspheres 
shows broad peaks from 190 to 240°C which is due to the 
physicochemical binding of the drug with the polymer 
structure. Hence the entrapment of drug in to Chitosan 
microsphere can be confirmed. 
 
Entrapment Efficiency: 
All the batches produced shows entrapment in the range 
of 77%-81% of drug into the microspheres (Table 1) the 
percentage of entrapment reduced as the concentration of 
crosslinking agent increased. 
Flow properties of powder: 
Table 2 shows the result of angle of repose, bulk density, 
tapped density, Carr’s index, Hausner ratio. Both the 
batches showed values within the limits required for the 
excellent flow properties. 
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(a) 
 
 
          (b) 
Figure 3: DSC Thermogram of (a) pure Salbutamol &(b) drug loaded microspheres 
 
Table 2: Flow properties of powder 
Parameter F1 F2 F3 F4 F5 
Angle of Repose ( 
0 
) 26
0 451 270 511 260 451 260 511 270 381 
Bulk Density (g/cm
3
) 0.7843 0.7692 0.7843 0.7834 0.7843 
Tapped Density 
(g/cm
3
) 
0.8163 0.8000 0.8334 0.8361 0.8331 
Carr’s Index 5.9215 4.2310 5.88231 7.69238 5.88451 
Hausner Ratio 1.03825 1.04004 1.06521 1.08334 1.05231 
Table 3: In-vitro drug release of Salbutamol sulphate-chitosan microspheres formulations 
 % Drug release 
Time (min.) F1 F2 F3 F4 F5 
5 28.67+1.44 19.50+1.65 27.86+1.45 16.72+1.71 19.50+1.56 
10 48.74+1.26 23.68+1.39 11.14+1.54 19.50+1.33 22.29+1.89 
15 43.01+1.33 22.29+1.62 26.47+1.33 15.32+1.38 13.93+1.86 
20 58.78+1.46 48.77+1.55 19.50+1.53 29.26+1.56 12.54+2.11 
25 88.88+1.47 96.14+1.47 32.04+1.50 48.77+1.35 33.44+1.98 
30 58.78+1.43 50.16+1.54 72.45+1.47 47.37+1.29 43.19+1.30 
45 74.55+1.25 66.88+1.68 45.98+1.43 57.13+1.23 62.70+1.21 
60 73.11+1.41 71.06+1.76 59.91+1.27 64.09+1.78 58.52+2.14 
90 68.8+1.35 71.06+1.56 68.27+1.21 58.52+2.17 58.52+1.25 
120 91.96+1.49 83.60+2.13 66.88+1.39 58.52+2.12 54.34+0.80 
S.D. (n=3) 
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Drug content: 
Table 1 shows the drug content of the formulations. The 
concentration of crosslinking agent affected the drug 
content. 
In-Vitro Dissolution study: 
The drug release of salbutamol sulphate from chitosan 
microspheres is shown in Table 3 (Fig. 4). From the in-
vitro dissolution study it was found that as the 
concentration of crosslinking agent was increased, the drug 
release was found to be decreased. This effect might be 
due to the less swelling ability of the chitosan 
microspheres due to increase in the crosslinking agent 
which impart more rigidity to the microspheres. 
 
 
Figure 4: In-Vitro Dissolution Study of Chitosan Microspheres 
CONCLUSION 
Spray drying is suitable technique for the preparation of 
microspheres. In this project this method was successfully 
used to prepare salbutamol sulphate loaded chitosan 
microspheres in presence & absence of crosslinking agent. 
Spray dried lactose (Inhalac®250) was used as a carrier in 
this study. Crosslinking agent citric acid was found to 
affect the surface properties, drug entrapment & drug 
release from microspheres. The drug loaded microsphere – 
carrier blend showed excellent flow properties. The 
particle size of all formulations was found to be in the 
range of 3.21µm – 3.25µm desired for dry powder inhaler. 
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